Durable Improvements Observed With Long-Term Guselkumab in Psoriatic Arthritis Trial
The DISCOVER-2 trial included 739 biologic-naïve adults with active psoriatic arthritis who were treated and followed for approximately 2 years.
Musculoskeletal Disorders
Zolgensma Labeling Updated With Additional Safety Information
Zolgensma is an adeno-associated virus vector-based gene therapy.
Abaloparatide Looks Promising for Men With Osteoporosis
The phase 3 ATOM study evaluated the efficacy and safety of abaloparatide in 228 men with osteoporosis.
First Interchangeable Biosimilar to Humira Gets FDA Approval
The interchangeable biosimilar product may be substituted for the reference product by a pharmacist.
Tymlos Label Update Highlights Bone Building Mechanism of Action
The update is based on data from an open-label, single-arm histomorphometry study.
Osteoporosis Treatments Compared to Assess Effects on Bone Mineral Density
The network meta-analysis compared the effects of 9 osteoporosis drugs on BMD.
FDA: New Warnings and Limitations Set for Certain JAK Inhibitors
The revisions are based on a completed review of a large randomized safety clinical trial, which included 4362 patients with rheumatoid arthritis.
Oral Myosin Inhibitor Fast Tracked for Becker Muscular Dystrophy
EDG-5506 is a selective, small molecule myosin inhibitor designed to protect injury-susceptible fast skeletal muscle fibers.
Botox Approval Expanded to Include 8 New Muscles for Upper Limb Spasticity
The indication for adult upper limb spasticity treatment now includes elbow and forearm muscles, intrinsic hand muscles, and thumb muscles.
Risk of Muscle Problems Based on Statin Therapy Intensity Investigated
Small increases in the risk for statin-associated muscle symptoms were observed for patients on high-intensity therapy.
- Loading...
Loading...
Next post in News
Loading... 
Loading...